TNBC is merely an operational term (hopefully soon to be replaced) to define cohorts of human breast cancers based upon what they are not, rather than what they actually are - which is clearly a collection of multiple distinct disease entities based upon genomic and transcriptomic characterization, each with prognostic as well as predictive implications for response to a variety of therapeutic drug classes, ranging from DNA damaging agents, to PARP inhibition, to immunotherapeutic agents, to ADCs, and potentially to hormonal manipulation of the androgen receptor. Here, AR is linked to breast cancer.